Presentation is loading. Please wait.

Presentation is loading. Please wait.

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis  Alice B. Gottlieb, MD, PhD,

Published byΘέκλα Βαμβακάς Modified over 6 years ago

Similar presentations

Presentation on theme: "Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis  Alice B. Gottlieb, MD, PhD,"— Presentation transcript:

1 Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis  Alice B. Gottlieb, MD, PhD, Kim A. Papp, MD, PhD, FRCPC, Charles A. Birbara, MD, Catherine L. Shuler, MS, Russel Burge, PhD, Janelle Erickson, PhD, Lisa Kerr, MSPH, Philip J. Mease, MD  Journal of the American Academy of Dermatology  Volume 79, Issue 3, Pages (September 2018) DOI: /j.jaad Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 PASI 75, PASI 90, and PASI 100 responses over 12 weeks (NRI) in IXE Q2W patients with plaque psoriasis, by PsA involvement. Comparisons between groups were based on the Cochrane-Mantel-Haenszel test stratified by study. IXE Q2W, Ixekizumab 80 mg every 2 weeks; NRI, nonresponder imputation; PASI, Psoriasis Area Severity Index; PsA, psoriatic arthritis. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Change from baseline in total DLQI score over 12 weeks in IXE Q2W patients with plaque psoriasis, by PsA involvement. Comparisons between groups were based on the Cochrane-Mantel-Haenszel test stratified by study. ∗P < .05, IXE Q2W patients with PsA versus without PsA. DLQI, Dermatology Life Quality Index; IXE Q2W, ixekizumab 80 mg every 2 weeks; PsA, psoriatic arthritis. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis  Alice B. Gottlieb, MD, PhD,"

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
Jeff Donovan, MD, PhD, FRCPC  JAAD Case Reports 

Jeff Donovan, MD, PhD, FRCPC  JAAD Case Reports 
Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,
Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 
A girl with a solitary red bulla

A girl with a solitary red bulla
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,
Psoriasis and suicidality: A systematic review and meta-analysis

Psoriasis and suicidality: A systematic review and meta-analysis
Baldness reversed by chemotherapy

Baldness reversed by chemotherapy
Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 
Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy of simvastatin in plaque psoriasis: A pilot study
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data  Bruce Strober, MD,

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data  Bruce Strober, MD,
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Deficiency of serum concentration of 25-hydroxyvitamin D correlates with severity of disease in chronic plaque psoriasis  Federica Ricceri, MD, Leonardo.

Deficiency of serum concentration of 25-hydroxyvitamin D correlates with severity of disease in chronic plaque psoriasis  Federica Ricceri, MD, Leonardo.
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

Similar presentations

Ads by Google